Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (51-60 of 437) with videos related to

Pageof 44
Sort By:
Future Oncology (London, England)|May 9, 2019
Nivolumab plus ipilimumab in non-small-cell lung cancerMartin Reck, Hossein Borghaei, Kenneth J O'Byrne
The European Respiratory Journal|February 23, 2013
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancerRudolf M Huber, Martin Reck, Michael Thomas
The Oncologist|June 30, 2016
The Future of Immunotherapy in the Treatment of Small Cell Lung CancerLeora Horn, Martin Reck, David R Spigel
Medizinische Klinik (Munich, Germany : 1983)|December 14, 2007
[Non-small cell lung cancer - diagnostics and stage-adapted therapy]David F Heigener, Martin Reck, Ulrich Gatzemeier
Deutsche Medizinische Wochenschrift (1946)|March 4, 2015
[Non-small cell lung cancer: news from immunotherapy]Niels Reinmuth, David F Heigener, Martin Reck
The New England Journal of Medicine|January 17, 2024
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. ReplyJohn V Heymach, David Harpole, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
The New England Journal of Medicine|September 20, 2018
Atezolizumab Treatment of Nonsquamous NSCLCMartin Reck, Robert M Jotte, Mark A Socinski
The Lancet. Respiratory Medicine|March 25, 2015
Targeting of MEK in lung cancer therapeuticsDavid F Heigener, David R Gandara, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Pageof 44

Showing results (51-60 of 437) with videos related to

Sort By:
Pageof 44
Future Oncology (London, England)|May 9, 2019
Nivolumab plus ipilimumab in non-small-cell lung cancerMartin Reck, Hossein Borghaei, Kenneth J O'Byrne
The European Respiratory Journal|February 23, 2013
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancerRudolf M Huber, Martin Reck, Michael Thomas
The Oncologist|June 30, 2016
The Future of Immunotherapy in the Treatment of Small Cell Lung CancerLeora Horn, Martin Reck, David R Spigel
Medizinische Klinik (Munich, Germany : 1983)|December 14, 2007
[Non-small cell lung cancer - diagnostics and stage-adapted therapy]David F Heigener, Martin Reck, Ulrich Gatzemeier
Deutsche Medizinische Wochenschrift (1946)|March 4, 2015
[Non-small cell lung cancer: news from immunotherapy]Niels Reinmuth, David F Heigener, Martin Reck
The New England Journal of Medicine|January 17, 2024
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. ReplyJohn V Heymach, David Harpole, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
The New England Journal of Medicine|September 20, 2018
Atezolizumab Treatment of Nonsquamous NSCLCMartin Reck, Robert M Jotte, Mark A Socinski
The Lancet. Respiratory Medicine|March 25, 2015
Targeting of MEK in lung cancer therapeuticsDavid F Heigener, David R Gandara, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Pageof 44